Form 8-K Valeant Pharmaceuticals For: Mar 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat
March 15, 2016 10:56 AM EDTEvercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.
"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.
".. today's results suggests that while... More
Valeant Pharma (VRX) Conference Call Ends
March 15, 2016 10:13 AM EDTValeant Pharma (NYSE: VRX) brutal conference call ends. With shares down 36.7% traders will be looking for the stock to possibly rally later in the session.
... MoreValeant Pharma (VRX) Misses Dramatically Reduced Expectations - BMO
March 15, 2016 9:00 AM EDTBMO Capital analyst, Alex Arfaei, posted an earnings flash on Valeant Pharmaceuticals' (NYSE: VRX) miss and guide down. The call is ongoing and began at 8:00AM.
This morning, Valeant reported unaudited 4Q15 revenues of $2.78B, 1% above consensus of $2.75B. Gross margin of 75.6%... More
The Single Most Important Catalyst for Valeant Pharma (VRX) Near-Term...
March 15, 2016 8:15 AM EDTValeant Pharma (NYSE: VRX) is down 15% after posting unaudited fourth quarter result and disappointing 2016 guidance. However, according to Evecore ISI analyst Umer Raffat, the single most important catalyst for Valeant near-term is timing for covenants/10-K filing to avoid default .
The all-important date of a default is March 30th + 30 days, so April 29.
Covenant... More
Valeant Pharma (VRX) Won't File 10-K Within 15-Day Extension Period
March 15, 2016 6:19 AM EDTValeant Pharma (NYSE: VRX) disclosed the following on Tuesday:
Item 2.02 Results of Operations and Financial Condition
On March 15, 2016, Valeant Pharmaceuticals International, Inc. (the Company) issued a press release announcing preliminary unaudited financial results for the fourth quarter ended December 31, 2015. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
The fourth quarter 2015 results are preliminary because, as previously announced, the Company has delayed the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 pending completion of the Companys... More
